December 14, 2017 10:03 AM EST
News Briefing

Pfiz­er's Ix­i­fi gets ap­proved as third Rem­i­cade biosim­i­lar; No­vo Nordisk li­cens­es re­MYN­D's di­a­betes pro­gram in po­ten­tial €350M deal

John Carroll

Editor & Founder

→ A third knock­off is com­ing af­ter J&J’s Rem­i­cade as the FDA ap­proved Pfiz­er’s $PFE mon­o­clon­al an­ti­body Ix­i­fi for a list of in­di­ca­tions in­clud­ing …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

A service from the Financial Times